A Phase 3 interventional study of Rexlemestrocel-L and Rexlemestrocel-L + HA Mixture in Degenerative Disc Disease, sponsored by Mesoblast, Ltd.. Completed at 48 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-19.
Sponsored by Mesoblast, Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.
Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 6th largest by enrollment of the 141 interventional ones that give a count, is one of 9 that started in 2015, is one of 16 in phase 3, and was the 96th registered.
462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.
Browse Intervertebral Disc Degeneration studies →41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
CGBio Inc. · Sites in United States
Ages 21–80
EicOsis Human Health Inc. · Sites in United States
Ages 18+
DiscGenics, Inc. · Sites in United States
Ages 18–75
VIVEX Biologics, Inc. · Sites in United States
Ages 22–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 20 · Phase 3 18 · Phase 4 8
First in 1998; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 404 is above the median of 60 across 256 interventional studies indexed under Intervertebral Disc Degeneration.
Median enrollment 57 across the 141 interventional studies, 118 across the 91 observational. Of the 132 that completed or were terminated, 44 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
165 of 232 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mesoblast, Ltd., one of the names counted as Mesoblast Limited. Under that name alone:
Mesoblast, Ltd. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Mesoblast Limited has 6 studies filed under Intervertebral Disc Degeneration — fewer than ten, so there is no comparison to draw.
17 of the studies in Intervertebral Disc Degeneration with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06325566Phase 3Mesoblast, Ltd.Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain | 2027-07 |
| NCT07254806Phase 3DiscGenics, Inc.A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease | 2027-11-24 |
| NCT05740176Synergy Spine SolutionsThe Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery | 2026-11 |
| NCT05037968Kuros Biosurgery AGMagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion | 2026-12 |
| NCT04388332Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)ACDF Using Structural Allograft vs. Tritanium C | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or combined with hyaluronic acid (HA) in participants with chronic low back pain (> 6 months) associated with moderate radiographic degenerative changes of a disc.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have documented diagnosis of moderate radiographic degeneration of an intervertebral disc from L1 to S1, with a disc suspected of causing chronic low back pain (CLBP) associated with moderate radiographic degeneration at a lumbar disc is defined as the following (participant must meet all of the listed conditions):
With or without contained disc protrusion at the index disc on MRI
e. Low back pain of at least 40mm and not more than 90mm of 100mm on low back pain visual analogue scale (VAS) (average pain over 24 hours)
f. Leg pain ≤20mm in both legs on a 100mm VAS scale
g. Oswestry disability index (ODI) score of at least 30 and no more than 90 on a 100 point scale.
Exclusion Criteria:
Any lumbar intradiscal injection, including , into the index or adjacent discs prior to treatment injection, with the exception of the following injections performed at least 2 weeks prior to study treatment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with saline on Day 0 (Visit 2).
Drug: Rexlemestrocel-L
Participants received rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with hyaluronic acid (HA) solution on Day 0 (Visit 2).
Drug: Rexlemestrocel-L + HA Mixture
Participants received saline solution as matching-placebo on Day 0 (Visit 2).
Drug: Placebo
Rexlemestrocel-L injection
Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected
Saline control solution
Overall Treatment Success: Bayesian Estimated Response Rate
Overall treatment success was determined based on number of responders who had composite response at both months 12 and 24 evaluated per specified criteria. A treatment responder with treatment success was defined as a participant who met the 3 criteria of a composite responder analysis as: 50% or greater reduction in the lower-back pain visual analogue scale (VAS) score; 15-point or greater reduction in the Oswestry Disability Index (ODI) score; and lack of post-treatment interventions at the treated level as of the study visit (Visits 6 \[12 months post-treatment\] and 8 \[24 months post-treatment\]). The average response rate (proportion of participants with response presented as Bayesian estimate\[BE\]) was based upon the average of multiple Bayesian simulations.
Time frame: Up to 24 months
Effectiveness Based on Pain Responders: Bayesian Estimated Response Rate
A participant was defined as a pain responder for a given study visit if they achieved at least a 50% reduction from Baseline in the lower-back pain VAS score (average pain over 24 hours), as reported during in-clinic assessment. The participant should be qualified as a pain responder at both 12 and 24 months post-treatment, and must not have received a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.
Time frame: Up to 24 months
Effectiveness Based on Functional Responders: Bayesian Estimated Response Rate
A participant was defined as a functional responder for a given study visit if they achieved at least a 15-point reduction from Baseline in ODI score, as reported during in-clinic assessment. The participant should be qualified as a functional responder at both 12 and 24 months post-treatment, and must not have received a post-treatment intervention through 24 months' follow-up; any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.
Time frame: Up to 24 months
Effectiveness Based on Treatment Success at 24 Months: Bayesian Estimated Response Rate
A treatment responder with treatment success was defined as a participant who met the 3 conditions of a composite responder analysis as: 50% or greater reduction in the lower-back pain VAS score; 15-point or greater reduction in ODI score; and lack of post-treatment interventions at the treated level as of the study visit. The participants qualified as responders if they satisfied the above conditions at the 24-month follow-up visit alone. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.
Time frame: Month 24
Effectiveness Based on Minimal Pain Responders at 24 Months: Bayesian Estimated Response Rate
A minimal pain responder was defined as a participant who achieved a lower-back pain VAS score (average pain over 24 hours) of 20 mm or less at the given study visit. The participants qualified as responders if they satisfied the above condition at 24 months post-treatment, and did not receive a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.
Time frame: Month 24
Effectiveness Based on Time to First Intervention Over 24 Months
The effectiveness of the study drug was evaluated based on its ability in increasing the time to additional interventions at the treated level over 24 months post-treatment. Kaplan-Meier estimates for the probability (expressed as a percentage) of participants to receive an intervention are presented.
Time frame: Up to Month 24
Effectiveness Based on Minimal Disability Responders at 24 Months: Bayesian Estimated Response Rate
A minimal disability responder was defined as a participant who achieved an ODI score of 20% or less at the given study visit. The participants qualified as responders if they satisfied the above condition at 24 months post-treatment, and did not receive a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.
Time frame: Month 24
Mean Change From Baseline in Low Back Pain Visual Analog Scale (VAS) Score at 1, 3, 6, 12, 18, 24, and 36 Months
Pain intensity was recorded on a horizontal 100 mm VAS and measured as the distance in millimeters from the left origin of the horizontal VAS line and the point indicated by the participant as representing their level of pain. A horizontal 100 mm VAS anchored on the left with the words "No Pain" and on the right with the words "Worst Possible Pain", was used to measure low back pain intensity. Scores were obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a slash placed by the participant to indicate the participant's level of pain. VAS ranges from 0 to 100, with higher scores indicating worst possible pain. A negative change from baseline indicates improvement.
Time frame: Months 1, 3, 6, 12, 18, 24, and 36
Starting on March 6, 2015, a total of 404 participants were enrolled at investigative sites in Australia and the United States.
| Milestone | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Started | 143 | 129 | 132 |
| Received treatment | 140 | 128 | 130 |
| Completed | 97 | 85 | 86 |
| Not completed | 46 | 44 | 46 |
| Withdrew: Adverse event | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 23 | 27 | 22 |
| Withdrew: Investigator decision | 3 | 3 | 2 |
| Withdrew: Lost to follow-up | 17 | 11 | 18 |
| Withdrew: Reason not specified | 3 | 2 | 2 |
Overall treatment success was determined based on number of responders who had composite response at both months 12 and 24 evaluated per specified criteria. A treatment responder with treatment success was defined as a participant who met the 3 criteria of a composite responder analysis as: 50% or greater reduction in the lower-back pain visual analogue scale (VAS) score; 15-point or greater reduction in the Oswestry Disability Index (ODI) score; and lack of post-treatment interventions at the treated level as of the study visit (Visits 6 \[12 months post-treatment\] and 8 \[24 months post-treatment\]). The average response rate (proportion of participants with response presented as Bayesian estimate\[BE\]) was based upon the average of multiple Bayesian simulations.
| BE proportion of participants | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Overall Treatment Success: Bayesian Estimated Response Rate | 0.267 ± 0.038 | 0.335 ± 0.043 | 0.313 ± 0.041 |
A participant was defined as a pain responder for a given study visit if they achieved at least a 50% reduction from Baseline in the lower-back pain VAS score (average pain over 24 hours), as reported during in-clinic assessment. The participant should be qualified as a pain responder at both 12 and 24 months post-treatment, and must not have received a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.
| BE proportion of participants | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Effectiveness Based on Pain Responders: Bayesian Estimated Response Rate | 0.352 ± 0.041 | 0.472 ± 0.045 | 0.388 ± 0.044 |
A participant was defined as a functional responder for a given study visit if they achieved at least a 15-point reduction from Baseline in ODI score, as reported during in-clinic assessment. The participant should be qualified as a functional responder at both 12 and 24 months post-treatment, and must not have received a post-treatment intervention through 24 months' follow-up; any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.
| BE proportion of participants | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Effectiveness Based on Functional Responders: Bayesian Estimated Response Rate | 0.378 ± 0.042 | 0.409 ± 0.045 | 0.413 ± 0.044 |
A treatment responder with treatment success was defined as a participant who met the 3 conditions of a composite responder analysis as: 50% or greater reduction in the lower-back pain VAS score; 15-point or greater reduction in ODI score; and lack of post-treatment interventions at the treated level as of the study visit. The participants qualified as responders if they satisfied the above conditions at the 24-month follow-up visit alone. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.
| BE proportion of participants | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Effectiveness Based on Treatment Success at 24 Months: Bayesian Estimated Response Rate | 0.353 ± 0.042 | 0.425 ± 0.045 | 0.391 ± 0.045 |
A minimal pain responder was defined as a participant who achieved a lower-back pain VAS score (average pain over 24 hours) of 20 mm or less at the given study visit. The participants qualified as responders if they satisfied the above condition at 24 months post-treatment, and did not receive a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.
| BE proportion of participants | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Effectiveness Based on Minimal Pain Responders at 24 Months: Bayesian Estimated Response Rate | 0.384 ± 0.043 | 0.495 ± 0.047 | 0.438 ± 0.046 |
The effectiveness of the study drug was evaluated based on its ability in increasing the time to additional interventions at the treated level over 24 months post-treatment. Kaplan-Meier estimates for the probability (expressed as a percentage) of participants to receive an intervention are presented.
| percentage probability | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Effectiveness Based on Time to First Intervention Over 24 Months | 0.1099 | 0.1003 | 0.0913 |
A minimal disability responder was defined as a participant who achieved an ODI score of 20% or less at the given study visit. The participants qualified as responders if they satisfied the above condition at 24 months post-treatment, and did not receive a post-treatment intervention through 24 months' follow-up. Any participant that did not have a minimum of a visit at 3 months (Study Visit 4) was considered a non-responder for this outcome measure. The average response rate (proportion of participants with response presented as BE) was based upon the average of multiple Bayesian simulations.
| BE proportion of participants | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Effectiveness Based on Minimal Disability Responders at 24 Months: Bayesian Estimated Response Rate | 0.394 ± 0.043 | 0.367 ± 0.045 | 0.440 ± 0.045 |
Pain intensity was recorded on a horizontal 100 mm VAS and measured as the distance in millimeters from the left origin of the horizontal VAS line and the point indicated by the participant as representing their level of pain. A horizontal 100 mm VAS anchored on the left with the words "No Pain" and on the right with the words "Worst Possible Pain", was used to measure low back pain intensity. Scores were obtained by measuring the distance in millimeters from the left origin of the line (0) to the point indicated with a slash placed by the participant to indicate the participant's level of pain. VAS ranges from 0 to 100, with higher scores indicating worst possible pain. A negative change from baseline indicates improvement.
| score on a scale | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Change from Baseline at Month 1 | -13.6 ± 2.14 | -17.3 ± 2.30 | -13.9 ± 2.32 |
| Change from Baseline at Month 3 | -19.1 ± 2.26 | -22.5 ± 2.41 | -17.6 ± 2.40 |
| Change from Baseline at Month 6 | -22.4 ± 2.34 | -24.9 ± 2.51 | -18.6 ± 2.48 |
| Change from Baseline at Month 12 | -23.3 ± 2.38 | -27.4 ± 2.55 | -19.0 ± 2.51 |
| Change from Baseline at Month 18 | -23.7 ± 2.56 | -25.1 ± 2.74 | -19.2 ± 2.70 |
| Change from Baseline at Month 24 | -20.8 ± 2.55 | -25.9 ± 2.74 | -18.3 ± 2.70 |
| Change from Baseline at Month 36 | -22.9 ± 2.62 | -25.1 ± 2.81 | -19.0 ± 2.77 |
Collected over Up to approximately 38 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rexlemestrocel-L | 0/143 (0%) | 17/140 (12.1%) | 111/140 (79.3%) |
| Rexlemestrocel-L + HA | 0/129 (0%) | 15/128 (11.7%) | 100/128 (78.1%) |
| Placebo | 0/132 (0%) | 10/130 (7.7%) | 98/130 (75.4%) |
| Event | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/140 | 0/128 | 4/130 |
| Acute myocardial infarctionCardiac disorders | 0/140 | 2/128 | 0/130 |
| Myocardial infarctionCardiac disorders | 0/140 | 2/128 | 0/130 |
| AppendicitisInfections and infestations | 2/140 | 1/128 | 1/130 |
| DiverticulitisInfections and infestations | 1/140 | 1/128 | 0/130 |
| PneumoniaInfections and infestations | 0/140 | 1/128 | 0/130 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/140 | 1/128 | 0/130 |
| Coronary artery diseaseCardiac disorders | 0/140 | 1/128 | 0/130 |
| Patella fractureInjury, poisoning and procedural complications | 0/140 | 1/128 | 0/130 |
| MigraineNervous system disorders | 0/140 | 1/128 | 0/130 |
| Event | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo |
|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 51/140 | 56/128 | 48/130 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 19/140 | 17/128 | 19/130 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/140 | 15/128 | 13/130 |
| HypoesthesiaNervous system disorders | 10/140 | 8/128 | 12/130 |
| ParesthesiaNervous system disorders | 11/140 | 5/128 | 4/130 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 10/140 | 7/128 | 10/130 |
| Neck painMusculoskeletal and connective tissue disorders | 5/140 | 6/128 | 10/130 |
| NauseaGastrointestinal disorders | 5/140 | 7/128 | 4/130 |
The Intent-to-treat (ITT) Analysis Set included all participants who were randomized, regardless of whether or not the participant was treated, or post-treatment measures were performed.
| Age, Continuous(years) | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo | Total |
|---|---|---|---|---|
| Mean | 42.1 ± 10.81 | 42.9 ± 11.66 | 43.3 ± 10.45 | 42.8 ± 10.96 |
| Sex: Female, Male(Participants) | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo | Total |
|---|---|---|---|---|
| Female | 60 | 54 | 61 | 175 |
| Male | 83 | 75 | 71 | 229 |
| Ethnicity (NIH/OMB)(Participants) | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 4 | 11 | 24 |
| Not Hispanic or Latino | 133 | 121 | 119 | 373 |
| Unknown or Not Reported | 1 | 4 | 2 | 7 |
| Race (NIH/OMB)(Participants) | Rexlemestrocel-L | Rexlemestrocel-L + HA | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 4 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 6 | 6 | 18 |
| White | 133 | 118 | 118 | 369 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 1 | 4 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2015 to primary completion in May 2020, 62 months.
Results were first posted in Jan 2022, 1 year 8 months after primary completion. A results delay was requested in May 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rexlemestrocel-l
Intervertebral Disc Degeneration →